Term ended Nov 15, 2024 · High confidence
20-year base term ended Nov 15, 2024
Held by Intarcia Therapeutics Inc.
Filed Dec 29, 2009 as application 12/655,397 · Granted Jun 21, 2011
Base term, 20 years from filing
Today
Term ended Nov 15, 2024
2004
2026
Clock starts
Nov 15, 2004
Nov 15, 2004
Term ended
Nov 15, 2024
Nov 15, 2024
Granted
Jun 21, 2011
Jun 21, 2011
base term
after the term ends
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,731,947, to Nov 15, 2024. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 15, 2004, when application 10/988,716, the earliest non-provisional in its chain, was filed (this one was filed Dec 29, 2009) | Nov 15, 2024 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,731,947) | resolves to Nov 15, 2024, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Nov 15, 2024 | High confidence |
This family
| Application 10/742,730 | Abandoned not computed | not computed |
| US 7,731,947 | In force May 2028 | May 2028 |
| Application PCT/US2004/038409 | PCT application no patent term | no patent term |
| Application 12/315,194 | Abandoned not computed | not computed |
| US 7,964,183 | this patent Nov 2024 | Nov 2024 |
| US 8,257,691 | Term ended Nov 2024 | Nov 2024 |
| US 8,398,967 | Term ended May 2024 | May 2024 |
| US 9,724,293 | Lapsed on the fee record Aug 2021 | Aug 2021 |
8 of 9 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 8, 2010 Reel 24953, frame 525 | Intarcia Therapeutics, Inc. | Oxford Finance Corporation; Silicon Valley Bank | Security Agreement |
| Sep 8, 2010 reel/frame not recorded | Intarcia Therapeutics, Inc. | Oxford Finance Corporation | Security Agreement |
| Sep 8, 2010 reel/frame not recorded | Intarcia Therapeutics, Inc. | Silicon Valley Bank | Security Agreement |
| Sep 23, 2011 Reel 26962, frame 62 | Oxford Finance Corporation; Silicon Valley Bank | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Nov 14, 2012 Reel 29299, frame 678 | Intarcia Therapeutics, Inc. | U.S. Bank National Association, as Collateral Agent | Security Agreement |
| Mar 23, 2015 Reel 35233, frame 470 | Alza Corporation | Intarcia Therapeutics Inc. | Assignment of Assignor's Interest |
| Mar 23, 2015 Reel 35233, frame 597 | Eliaz, Rom Ezer; Zhang, Yuanpeng; Rohloff, Catherine Manya; Weeks, Eric William; Junnarkar, Gunjan | Alza Corporation | Assignment of Assignor's Interest |
| Oct 23, 2015 Reel 36942, frame 544 | U.S. Bank National Association, as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Oct 9, 2019 Reel 50673, frame 20 | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Midcap Financial Trust, As Agent | Security Interest |
| Oct 23, 2019 Reel 50801, frame 267 | Intarcia Therapeutics, Inc. | Baupost Private Investments Bviv-3, L.L.C., as Collateral Agent | Security Interest |
| Jan 29, 2020 Reel 51739, frame 453 | Baupost Private Investments Bviv-3, L.L.C. as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 Reel 52433, frame 1 | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Ireland Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,731,947, ends no earlier than this term, so it caps nothing.
Citations
30
later US patents cite this one
That is top 25% of utility patents granted in 2011 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.